
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd has shown impressive revenue performance, with 4Q25 revenues reaching $174.4 million, representing a 4% quarter-over-quarter increase and an 8% year-over-year growth, driven by strong domestic sales of its Optune Gio device. Additionally, the company has reported notable international growth, particularly with the national reimbursement in Spain expected to enhance revenue streams in 2026. The ongoing clinical trials, including TRIDENT, which has the potential to expand patient access to the Tumor Treating Fields (TTFields) technology, further supports a positive outlook for sustained revenue growth in the coming years.
Bears say
NovoCure Ltd. is facing significant challenges in its revenue projections, with 2026 estimates for glioblastoma (GBM) reduced from $702 million to $690 million, and total revenue expectations cut from $738.9 million to $711.3 million. The company’s efforts in the non-small cell lung cancer (NSCLC) market have been particularly hampered, leading to a decrease in global peak sales estimates to $483 million from $623 million as launch challenges persist. Additionally, considerable risks undermine the company's growth outlook, including potential safety signals from clinical programs, lower-than-expected efficacy, increased competition, regulatory concerns, and issues related to intellectual property protection.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares